drugset

drugset / Trial / NCT00532506

Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus

NCT00532506 ↗

Phase 2 Completed Sanwa Kagaku Kenkyusho Co., Ltd.

RandomizedParallel-groupDouble-blind

Summary

The purpose of this study is to evaluate the clinical efficacy and safety of SK-0403 in patients with Type2 Diabetes Mellitus

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anagliptin	Small molecule	—	—

Indications